Management of autoimmune cytopenia complicating chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 50, Issue 6, 2009, Pages 863-864

  Zent, Clive S ^a   Shanafelt, Tait ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; OFATUMUMAB; PENTOSTATIN; RITUXIMAB;

AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CYTOPENIA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NOTE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PURE RED CELL ANEMIA; TREATMENT RESPONSE;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 68449101105     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902919226     Document Type: Note

References (10)

1. Zent CS, Ding W, Schwager SM, Reinalda MS, Hoyer JD, Jelinek DF, et al. The prognostic significance of cytopenia in chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL). Br J Haematol 2008;141:615-621.
2. Mauro F, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: Clinical, therapeutic, and prognostic features. Blood 2000;95:2786-2792.
3. Hamblin T. Autoimmune disease and its management in chronic lymphocytic leukemia. In: Cheson B, editor. Chronic Lymphocytic Leukemias, 2 edn. New York: Marcel Dekker; 2001. pp 435-458.
4. Dearden C, Wade R, Else M, Richards S, Milligan D, Hamblin T, et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: A beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 2008;111:1820-1826.
5. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-234.
6. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-205.
7. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the international workshop on chronic lymphocytic leukemia (IWCLL) updating the national cancer institute-working group (NCI-WG) 1996 guidelines. Blood 2008;111:5446-5456.
8. Ding W, Zent CS. Diagnosis and management of autoimmune complications of chronic lymphocytic leukemia/small lymphocytic lymphoma. Clin Adv Hematol Oncol 2007; 5:257-261.
9. Myint H, Copplestone J, Orchard J, Craig V, Curtis D, Prentice A, et al. Fludarabine-related autoimmune hemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995;91:341-344.
10. Kaufman M, Limaye SA, Driscoll N, Johnson C, Caramanica A, Lebowicz Y, et al. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:892-899.